What are the recommended dosing regimens of enoxaparin (Lovenox) for venous thromboembolism prophylaxis and treatment, including adjustments for renal impairment, elderly patients, low body weight, and severe renal impairment?

Enoxaparin (Lovenox) Dosing for VTE Prophylaxis and Treatment

For VTE prophylaxis in patients with severe renal impairment (CrCl <30 mL/min), use enoxaparin 30 mg subcutaneously once daily; for VTE treatment in this population, use 1 mg/kg subcutaneously once every 24 hours. These are the only FDA-approved and guideline-supported dose adjustments with specific manufacturer recommendations among all low-molecular-weight heparins 1.

Standard Dosing Regimens

VTE Prophylaxis

Hospitalized Medical Patients:

• Standard dose: 40 mg subcutaneously once daily 2, 3
• Duration: Length of hospital stay or until fully ambulatory 2, 3

Surgical Patients:

• 40 mg subcutaneously once daily starting 10-12 hours preoperatively, OR
• 20 mg subcutaneously 2-4 hours preoperatively, then 40 mg once daily thereafter 2, 3
• Duration: Minimum 7-10 days; consider extended prophylaxis up to 4 weeks for high-risk patients 2, 3

VTE Treatment

Initial Treatment:

• 1 mg/kg subcutaneously every 12 hours, OR
• 1.5 mg/kg subcutaneously once daily 2, 3

Long-term Treatment:

• 1.5 mg/kg once daily, OR
• 1 mg/kg every 12 hours 2, 3

Renal Impairment Adjustments

Severe Renal Impairment (CrCl <30 mL/min)

This is where enoxaparin has the clearest evidence and FDA approval for dose reduction:

• Prophylaxis: 30 mg subcutaneously once daily 1, 4
• Treatment: 1 mg/kg subcutaneously once every 24 hours (not twice daily) 1, 4

The rationale is compelling: enoxaparin clearance decreases by 44% in severe renal impairment, and standard unadjusted therapeutic doses carry a 2- to 3-fold increased bleeding risk in this population 1. These are manufacturer-specified recommendations supported by meta-analyses demonstrating significant bleeding risk with standard dosing 1.

Moderate Renal Impairment (CrCl 30-60 mL/min)

Exercise caution and consider dose reduction, though specific recommendations are less established. Evidence suggests enoxaparin clearance is reduced by 31% in moderate renal impairment 1. Some experts recommend dose adjustments for CrCl <50 mL/min 1. The 2012 CHEST guidelines suggest dose reduction for severe renal insufficiency (Grade 2C) 5, and research supports adjustments even in moderate impairment 6.

Practical approach for moderate impairment:

• Consider reducing treatment doses to 0.8 mg/kg every 12 hours for CrCl 30-50 mL/min 6
• Monitor anti-Xa levels if available (target 0.5-1.2 IU/mL for treatment, measured 4 hours post-dose) 1

Low Body Weight Patients (<50 kg)

Use caution with standard dosing in patients <50 kg, as limited data exist for this population 1. Recent evidence suggests:

For prophylaxis in low body weight patients:

• Consider 30 mg subcutaneously once daily rather than 40 mg 7, 8, 9
• A 2024 multicenter study (n=419) showed reduced-dose prophylaxis (30 mg daily or heparin 5000 units every 12 hours) in patients ≤50 kg resulted in significantly lower composite bleeding (5% vs 12.5%, p=0.02) with similar VTE rates 7
• Weight-based dosing (0.5 mg/kg daily) has been successfully used in extremely underweight patients with anti-Xa monitoring 10

For treatment in low body weight patients:

• Standard weight-based dosing (1 mg/kg every 12 hours or 1.5 mg/kg once daily) appears appropriate 8

Critical pitfall: Patients <50 kg are at higher bleeding risk with standard fixed doses. The evidence increasingly supports dose reduction for prophylaxis but not necessarily for treatment 1, 7, 8.

Elderly Patients (≥70 years)

Standard dosing can generally be used, but exercise heightened caution, particularly in those with renal impairment or low body weight 1.

Important contraindication: Avoid tinzaparin in patients ≥70 years with renal insufficiency (CrCl <60 mL/min) due to significantly higher mortality (11.2% vs 6.3% with UFH, p=0.049) demonstrated in a randomized trial that was terminated early 1.

For elderly patients with acute STEMI:

• Age <75 years: 30 mg IV bolus, then 1 mg/kg subcutaneously every 12 hours 11
• Age ≥75 years: 0.75 mg/kg subcutaneously every 12 hours (no IV bolus) 11

Obese Patients

For prophylaxis in morbidly obese patients (BMI ≥40 kg/m²):

• Use 40 mg subcutaneously twice daily rather than once daily 1, 8
• Consider even higher doses for BMI ≥50 kg/m² 8
• Standard 5000 IU dalteparin daily was ineffective in patients with BMI ≥40 kg/m² 1

For treatment:

• Standard weight-based dosing appears appropriate, though optimal dosing remains unclear for patients >120 kg 2
• Consider anti-Xa monitoring in extreme obesity 8, 12

Monitoring Considerations

Routine anti-Xa monitoring is not required for most patients 5. However, consider monitoring in:

• Severe or moderate renal impairment (CrCl <50 mL/min)
• Extremes of body weight (<50 kg or BMI ≥40 kg/m²)
• Pregnancy
• Recurrent VTE despite therapy

Target anti-Xa levels:

• Prophylaxis: 0.2-0.4 IU/mL (peak, 4 hours post-dose)
• Treatment: 0.5-1.2 IU/mL (peak, 4 hours post-dose) 1, 6

Measure after 3-4 doses to achieve steady state 1.

Critical Warnings

Avoid enoxaparin in:

• Active major bleeding
• Heparin-induced thrombocytopenia (HIT) history 1
• CrCl <30 mL/min without dose adjustment 2

Monitor platelet counts every 2-3 days from day 4-14 in patients with HIT risk ≥1% 13.

Do not interchange enoxaparin with other LMWHs or unfractionated heparin without appropriate dose adjustments, as this increases bleeding risk 1, 13.